|
Number
|
68
|
24
|
|
Disease duration (months)
|
27 (0-268)
|
11 (1-188)
|
|
Outpatients
|
61 (90%)
|
16 (67%)
|
|
Previous hospitalizations
|
2 (0-14)
|
2 (0-6)
|
|
Previous resective surgery
|
33 (49%)
|
-
|
|
Localization
| | |
|
L1: Terminal ileum
|
28 (41%)
| |
|
L2: Colon
|
21 (31%)
| |
|
L3: Ileocolon
|
15 (22%)
| |
|
L4: Upper gastrointestinal
|
4 (6%)
| |
|
E1: Ulcerative proctitis
| |
2 (8%)
|
|
E2: Left-sided Ulcerative colitis
| |
7 (29%)
|
|
E3: Extensive Ulcerative colitis
| |
15 (63%)
|
|
Behavior
| | |
|
B1: inflammatory
|
27 (40%)
| |
|
B2: stricturing
|
26 (38%)
| |
|
B3: penetrating
|
15 (22%)
| |
|
Perianal disease
|
24 (35%)
|
1 (4%)
|
|
Indication of treatment
| | |
|
Steroid dependence
|
24 (35%)
|
15 (62%)
|
|
Induction of remission
|
10 (15%)
|
5 (21%)
|
|
Maintenance after severe flare
|
1 (1%)
|
4 (17%)
|
|
Fistulizing disease
|
8 (12%)
|
-
|
|
Prevention of recurrence
|
21 (31%)
|
-
|
|
Extensive disease
|
4 (6%)
|
-
|
|
Concomitant treatment
| | |
|
Steroids
|
35 (52%)
|
17 (71%)
|
|
Infliximab
|
8 (12%)
|
-
|
|
Antibiotics
|
18 (27%)
|
1 (4%)
|
|
Mesalamine
|
2 (3%)
|
5 (21%)
|
|
Topical treatment
|
1 (2%)
|
19 (79%)
|
